Regulations and compliance · Practical guide

GMP blank forms: which issued copies were actually used?

An approved template offers little protection against outdated printouts, missing sheets or rewritten entries. The gap often lies between approval of the template and filing of the completed record. Control the issue, return and replacement of important blank forms in proportion to their use.

Table of contents

At a glance

How should blank forms be controlled?

GMP records need suitable current templates and traceable completed records. For issued blank documents, PIC/S PI 041-1 section 8.4 expects unique identifiers and a register, justified replacements and reconciliation of critical forms after use. Implement controls according to data risk and criticality. A newly issued clean sheet must not displace the original erroneous entry without a traceable link.

  • Approved template and issued copy are distinct control items.
  • Replacement forms are part of the detection chain with reason and origin.
  • A numerically complete traceback does not prove correct content-based documentation.

1. Distinguish between draft and final version of documentation and records

In the Human Medicines GMP Scope, Chapter 4 describes requirements for controlled documents and comprehensible records. A template specifies what needs to be entered. The actual completed copy documents a concrete activity. Both need appropriate controls, but perform different tasks.

An updated template does not retrospectively modify already completed records. Conversely, the correct archiving of a completed form does not prove that the then-current template version was used during its preparation. Ensure that the required version and workflow references are captured such that this linkage remains clear and understandable in the future.

Sources: [1] [2]

2. Select the form control based on the form's significance

PIC/S addresses the control of templates and blank documents on a risk-based basis. A critical production or laboratory form may require different issuance and recall controls compared to a clearly marked, purely reference copy. The FDA identifies numbered forms or controlled sets as potential measures within the Drug CGMP context.

The following internal matrix serves as a decision-support tool. It does not require central numbering of every individual expression. What is critical is identifying instances where uncontrolled reuse, substitution, or loss could compromise GMP traceability.

Own selection matrix for formulation control
Document typeMajor riskRelevant control question
Critical empty manufacturing batch Undetected additional copies or replacements Is release and retention traceable?
Original entry form Discard or reject unfavorable data Is the original record retained?
Electronic fillable template Incorrect status or uncontrolled modification Are template, authorization, and record creation governed?
Pure reference copy Confusion with an original form intended for completion Is their intended use clearly defined?
Continuation sheet Loss of correlation Is it clearly associated with the process?

Sources: [2] [3] [1]

3. Edition to be designed so that work remains feasible

A reasonable release combines a valid reference version, a copy, and the intended process. Depending on risk, this may be achieved through numbered lines, controlled printing, or an appropriate electronic procedure. Availability at the work location remains critical: a cumbersome release process should not result in actual reliance on interim notes and subsequent transfer.

Also specify how additional requirements are handled. The mere presence of an extra sheet is not automatically suspicious. Concern arises when it becomes impossible to determine which examples originally existed, why additional copies were required, and which of those actually contain records.

Sources: [2] [1]

4. Example: One sheet remains unopened

For a given process, twelve controlled samples are initially issued. Eight are returned completed, one is damaged, two remain unused, and one is missing. For the damaged sample, a justified replacement is issued and later returned completed. In total, thirteen samples were issued.

The final score is nine completed, one damaged, two unused and one unexplained. 9 + 1 + 2 + 1 results 13. The mathematical agreement does not close the process anyway: the whereabouts of a copy are open. The nine completed sheets must also be checked in terms of content.

Own completed register for release and retention status
StatusCountEvidence in the exampleAssessment
Originally issued 12 List of distributions with identifiers Starting inventory
Issued as an additional replacement 1 Rationale and reference for the damaged sheet Total Issue 13
Filled back 9 8 original plus 1 replacement Substance content verification remains required
Damaged returned 1 Original sheet remains assigned Does not fully replace
Unused returned 2 Location and handling documented No new record fabricated or faked
Remaining unresolved 1 Open identification in the register Investigation and impact assessment evaluation

Sources: [2] [3]

5. Don't just write off flawed sheets cleanly

When a record already contains entries, it is no longer merely an empty form. A replacement must take into account the original state and the rationale for the replacement. The FDA specifies that defective forms should remain with a justification for the replacement. The specific acceptance and review shall be in accordance with your established procedure.

A new batch may not indicate an earlier date or an original record. If information transfer is required, the transfer must be clearly identifiable and based on reliable original documentation. An illegible original entry must not be replaced by a calculated or estimated value.

Sources: [3] [1] [2]

Further reading:

6. Digital dossiers have the same core question, addressed by different means

For an electronic template, establish the valid version, permission to make changes and how the actual record is generated. A PDF in an approved folder leaves questions open if users can amend it locally or continue using superseded copies.

A technical lock can help, but must align with intended workflows. For example, verify whether a stored record can be inadvertently reset and re-entered later. The question about the process remains: Which data were generated when, and is the data history traceable to its origin?

Sources: [4] [2] [1]

7. Purposefully evaluate deviations in the backflow

If an exemplar is missing, first clarify its intended use and whether relevant data may have been generated on it. An unused, controlled-return form sheet should be evaluated differently from a missing sheet that may contain original entry data. Pure quantity reconciliation alone cannot substitute for these distinctions.

The quality system should enable appropriate investigations and corrective actions. Not every deviation necessitates the same level of escalation or automatically triggers a separate CAPA. However, recurring losses, unclear backup procedures, or indications of selective documentation may point to more extensive underlying causes.

Sources: [2] [5]

8. Checklist for a feasible formular guidance

Start with forms where loss, replacement, or outdated versions significantly impact critical documentation. This enables targeted control, rather than establishing a cumbersome counting procedure for every printout.

The following internal list combines template guidance and actual recordkeeping. A complete register is only part of the documentation trace; readability, timely entries, and technically accurate content remain required.

  • Critical fillable forms from reference copies are distinguished.
  • Valid template status and availability at the workplace regulated.
  • Issued specimens appropriately assigned.
  • Supplementary sheets and replacements attached with origin and reason specified.
  • Already created original records received during replacement.
  • Unused, damaged and unexplained specimens treated separately.
  • Return counts and the contents of the forms were assessed separately.

Sources: [1] [2] [3]

Project experience and collaboration

Test form issue, return and replacement

With the process owners and Document Control, we trace a critical form from the effective template to the completed record. We include additional pages, damaged sheets and justified replacements. A controlled register may suit a small process. Multiple issuance points may need other technical and organisational controls. We check whether missing copies are detected and the original record is preserved. The process should work at the point of use without encouraging a workaround on scrap paper.

Frequently asked questions about Controlling blank forms

Must each blank form be continuously numbered?

No, not every printout needs to be treated as a critical blank form. PIC/S requires a unique identifier and a registry entry for issued blank documents; for critical forms, a post-use reconciliation is required (8.4). The FDA identifies numbered form sets as an appropriate control, provided they are suitable (Question 6). Pure reference printouts should be handled differently: PIC/S permits exemption from post-use reconciliation if the creation date and limited validity period are clearly visible.

Sources: [2] [3]

Is a released Word template sufficient?

It may be part of the solution. Additionally, it must be clarified how the correct version is used, who is authorized to modify it, and how the actual record is generated. Uncontrolled local copies or arbitrarily replaceable completed files may still result in traceability gaps, even if the approved master template is available.

Sources: [1] [4]

Can damaged reels be replaced with new ones?

Yes, if the replacement is appropriately addressed and traceable. Existing original entries must not disappear without notice. Ensure that the basis, origin reference, and, if applicable, the controlled transfer is documented. A fresh clean sheet is not a substitute for the data history.

Sources: [3] [2]

What happens to unused forms?

Review the retention of unused copies. Following PIC/S PI 041-1, unused copies shall be devalued and destroyed or returned to secure storage (8.4). This does not imply unbounded retention of unused copies. However, previously documented or damaged original records must not be treated as blank reserve sheets.

Sources: [2]

Is a missing sheet automatically a data integrity violation?

It is first necessary to clarify the finding. Verify whether relevant data may have been generated and assess the associated uncertainty. The significance depends on the content and the process. A simple computational reclassification to "unused" without supporting evidence does not resolve the issue.

Sources: [2] [5]

May we first record values on a note card?

No. PIC/S PI 041-1 requires that your procedures prohibit the use of uncontrolled documents and preliminary records on sticky notes (8.4). If a value is nonetheless first recorded on a sticky note, the original record must not be lost during transfer. Ensure the original record is preserved, establish a clear reference to the corresponding record, and evaluate the procedure within your process. Ensure that appropriate controlled forms or entry options are available at the workplace.

Sources: [1] [2]

How are additional pages assigned?

Assign the additional sheet and specific procedure unambiguously, for example, through a common identifier and a regulated page supplementation. The completeness and sequence must remain clearly visible. Additionally, specify who is authorized to issue additional pages and how their retention is reconciled with the main record.

Sources: [1] [2]

Do pure reference prints require the same control?

Not mandatory. PIC/S distinguishes the purpose of documents and the associated risks. A simple reference copy should not be confused with a form specifically designated for original recordkeeping. Therefore, labeling and distribution scope may differ.

Sources: [2]

Does a fully balanced register provide evidence of correct documentation?

No. The reconciliation shows the declared holdings of samples. Whether entries are correct, legible, timely, and professionally complete must be verified separately. In the example of this article, one sample remains explicitly unexplained despite the calculated total sum.

Sources: [1] [2]

When should the form process be reviewed?

When repeated instances of replacement without a justifiable reason, missing sections, or preliminary side recordings occur, investigate root causes such as missing fields, poor availability, or unclear responsibility. The corrective action should improve the actual process, not merely generate an additional signature.

Sources: [5] [2]

Sources and review date

Source date: 7 October 2026. The technical examples relate to human medicinal product GMP. FDA statements are contextualized within the applicable U.S. medicinal product framework. Tables and numerical examples are intended as internal work aids.

  1. European Commission: EU GMP Chapter 4, DocumentationJanuary 2011; in effect since 30.06.2011; Principle; §§4.1–4.9, in particular timely recording 4.8 and visible correction 4.9; §§4.10–4.12 Storage
  2. PIC/S: PI 041-1, Data Management and IntegrityPIC/S PI 041-1, 1 July 2021. See section 3.7 for status, sections 7.5–7.8 and 8.1–8.8, sections 9.1.5 and 9.3 and 9.5–9.10, section 12.1 and the glossary.
  3. FDA: Data Integrity and Compliance With Drug CGMP, Questions and AnswersFinal Guidance, December 2018; Section III Q1(b)–(d), Q2, Q4–6, Q7–10, Q12–13, and Q18
  4. European Commission: EU GMP Annex 11, Computerised SystemsRevision January 2011; from 30.06.2011; Principle; §§1,4,5,7,9–13,17; §12.4 Identity, Date and Time; §10 controlled changes
  5. European Commission: EU GMP Chapter 1, Pharmaceutical Quality SystemRevision 2013; effective from 31.01.2013; §1.4(xii)–(xiv): proactive change evaluation, post-evaluation, and root cause analysis/CAPA; §1.5 Management

Sources checked: .

Daniel Herrmann, Daniel Herrmann Consulting

Daniel Herrmann Consulting

Control forms from the valid version up to the record.

We help you link critical documents and records with appropriate controls – for paper workflows, digital forms, and their transitions.

  • Computer system validation →

    Bring your GxP systems into validated operation, from laboratory software, MES and eQMS to ERP. We define the scope, plan risk-based tests using GAMP 5 and hand the evidence to QA for release.

Send a project enquiry Customer testimonials →